KAYLA TEIVES: Open Payments
NPI 1124565239 · CLARKSVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,135 in 80 payments from 15 companies in 2025. Trend: 2023 $2,192 · 2024 $1,088 · 2025 $1,135
Food & beverage: $1,135
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $239 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $215 |
| Neurocrine BioSciences, Inc. | 9 | $156 |
| Alkermes, Inc. | 5 | $99 |
| Janssen Pharmaceuticals, Inc | 4 | $79 |
| Lundbeck LLC | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| AstraZeneca Pharmaceuticals LP | 2 | $51 |
| Novo Nordisk Inc | 1 | $22 |
Products named: CAPLYTA, VRAYLAR, INGREZZA, ARISTADA, INVEGA SUSTENNA, MAVYRET, ABILIFY ASIMTUFII, TRINTELLIX.
Industry payments across IN — which companies pay providers there.
